JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online January 15, 2010, 10.2967/jnumed.108.058651
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.058651v1
51/2/311    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Sgouros, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sgouros, G.
Journal of Nuclear Medicine Vol. 51 No. 2 311-328
© 2010 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.058651

Special Contribution

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy*

George Sgouros1, John C. Roeske2, Michael R. McDevitt3, Stig Palm4, Barry J. Allen5, Darrell R. Fisher6, A. Bertrand Brill7, Hong Song1, Roger W. Howell8, Gamal Akabani9 In collaboration with the SNM MIRD Committee: Wesley E. Bolch, A. Bertrand Brill, Darrell R. Fisher, Roger W. Howell, Ruby F. Meredith, George Sgouros (Chair), Barry W. Wessels, and Pat B. Zanzonico

1 Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland; 2 Department of Radiation Oncology, Loyola University Medical Center, Maywood, Illinois; 3 Departments of Medicine and Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; 4 Dosimetry and Medical Radiation Physics Section, International Atomic Energy Agency, Vienna, Austria; 5 Centre for Experimental Radiation Oncology, St. George Cancer Centre, Kogarah, Australia; 6 Radioisotopes Program, Pacific Northwest National Laboratory, Richland, Washington; 7 Department of Radiology, Vanderbilt University, Nashville, Tennessee; 8 Division of Radiation Research, Department of Radiology, New Jersey Medical School Cancer Center, University of Medicine and Dentistry of New Jersey, Newark, New Jersey; and 9 Department of Nuclear Engineering, Texas A&M University, College Station, Texas

Correspondence: For correspondence or reprints contact: George Sgouros, Department of Radiology and Radiological Science, CRB II 4M61/1550 Orleans St., School of Medicine, Johns Hopkins University, Baltimore, MD 21231. E-mail: gsgouros{at}jhmi.edu

The potential of {alpha}-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of {alpha}-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with {alpha}-particle emitters. Although {alpha}-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted {alpha}-particle emitter therapy and to provide guidance and recommendations for human {alpha}-particle emitter dosimetry.

Key Words: {alpha}-particle emitters • human {alpha}-particle emitter dosimetry • targeted {alpha}-particle emitter therapy

* Unabridged version of this document is available at: http://interactive.snm.org/index.cfm?PageID=1110&RPID=2199&FileID=144234.

COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2010 51: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2010 by the Society of Nuclear Medicine.